ECEESPE2025 ePoster Presentations Reproductive and Developmental Endocrinology (128 abstracts)
Circulating anti-müllerian hormone and inhibin b levels in reproductive disorders causing oligo/amenorrhoea
Sandhi Nyunt 1,2 , Bijal Patel 1,2 , Arthur Yeung 1,2 , Maria Phylactou 1,2 , Jovanna Tsoutsouki 1 , Kanyada Koysombat 1,2 , Megan Young 1 , Aaran Patel 1,2 , Aureliane Pierret 1,2 , Elisabeth Daniels 1,2 , Ambreen Qayum 1,2 , Yusra Omar 1 , Pei Eng 1,2 , Edouard G Mills 1,2 , Simon Hanassab 3 , Lisa Webber 1 , Channa Jayasena 1,2 , Tricia Tan 1,2 , Richard Quinton 1 , Sophie Clarke 4 , Alexander Comninos 1,2 , Ali Abbara 1,2 & Waljit Dhillo 1,2
1Imperial College London, Department of Metabolism, Digestion and Reproduction, London, United Kingdom; 2Imperial College Healthcare NHS Trust, Department of Endocrinology, London, United Kingdom; 3Imperial College London, Department of Computing, London, United Kingdom; 4University College Hospitals NHS Foundation Trust, United Kingdom, London, United Kingdom
JOINT2390
Background: Anti-Müllerian Hormone (AMH) and Inhibin B (INB) are key glycoprotein hormones produced by granulosa cells that serve as key markers of ovarian reserve. INB modulates FSH secretion at the pituitary gland, whilst AMH stimulates hypothalamic GnRH neuronal pulsatility in vitro. Anovulatory menstrual disturbance results from reproductive disorders including polycystic ovary syndrome (PCOS), functional hypothalamic amenorrhea (FHA), and congenital hypogonadotropic hypogonadism (CHH). The prevalence of polycystic ovarian morphology on ultrasound is increased in FHA and PCOS. However, there is limited data directly comparing AMH and INB in women with PCOS, FHA, and CHH.
Methods: We investigated levels of AMH and INB in women aged 18-35yrs classified as: healthy controls (n = 46), PCOS (n = 73), FHA (n = 44), or CHH (n = 8). Groups were compared by Kruskal Wallis test with post hoc Dunn’s test and continuous variables by correlation.
Results: Median (IQR) AMH (pmol/l)was higher in PCOS 42.9 (27.75–56.95) than in healthy controls 22.1 (14.0–26.85; P <0.0001), FHA 25.8 (14.0–30.44; P = 0.0018), and CHH 4.3 (8.4–21.45; P = 0.0001). AMH differentiated PCOS from FHA, with an area under the ROC curve (auROC) of 0.705; P = 0.0002, whereas for lean PCOS (BMI<25kg/m2) vs FHA, auROC was 0.762; P <0.0001. AMH was positively correlated with LH in PCOS (P = 0.003, r = 0.34), but negatively in FHA (P = 0.017, r=-0.21). Additionally, AMH negatively correlated with FSH in FHA (P = 0.001, r=-0.49) and healthy controls (P = 0.005, r=-0.41). Among women with PCOS, higher BMI was associated with lower AMH levels (P = 0.0139, r=-0.287). Median INB levels (ng/l)were similar in PCOS (77) and healthy controls (79), but lower in FHA (58, P = 0.0421) and markedly reduced in CHH (7, P = 0.0001). INB reliably differentiated CHH from FHA (auROC 0.98; P <0.0001). Women with PCOS and obesity (BMI>30kg/m2) had lower INB levels than their non-obese counterparts (67 vs. 87-90; P = 0.015) with a negative correlation between INB and BMI (P = 0.0108, r=-0.297). INB positively correlated with LH (P = 0.002, r = 0.46), and FSH (P = 0.002, r = 0.45) in FHA, as well as with FSH in healthy controls (P = 0.029, r = 0.32).
Conclusion: Although AMH was slightly higher in FHA than healthy women, it was markedly elevated in women with PCOS. INB levels were lower in FHA but markedly reduced in CHH. Both AMH and INB decreased with increasing BMI. Despite its established role in inhibiting FSH secretion, INB positively correlated with FSH in both FHA and healthy women. These data suggest that AMH and INB are valuable biomarkers in the evaluation of anovulatory menstrual disturbances.
Volume 110
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2025 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more